Eslicarbazepine acetate is associated with lower plasma levels of levonorgestrel, potentially decreasing hormonal contraceptive effectiveness. Additional or alternative non-hormonal birth control is recommended.
Source: NLP:eslicarbazepine acetate
Levonorgestrel Interactions
Brand names: Skyla
Progestin · Progestin-containing Intrauterine System
Route: Intrauterine
Contraindications
4 CONTRAINDICATIONS The use of Skyla is contraindicated when one or more of the following conditions exist: • Pregnancy or suspicion of pregnancy [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.1 )] • For use as post-coital contraception (emergency contraception) • Congenital or acquired uterine anomaly including fibroids, that distorts the uterine cavity • Acute pelvic inflammatory disease (PID) or a history of PID unless there has been a subsequent intrauterine pregnancy [see Warnings and Precautions ( 5.4 )] • Postpartum endometritis or infected abortion in the past 3 months • Known or suspected uterine or cervical malignancy • Known or suspected breast cancer or other progestin-sensitive cancer, now or in the past • Uterine bleeding of unknown etiology • Untreated acute cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections until infection is controlled • Acute liver disease or liver tumor (benign or malignant) • Conditions associated with increased susceptibility to pelvic infections [see Warnings and Precautions ( 5.4 )] • A previously inserted intrauterine device (IUD) that has not been removed • Hypersensitivity to any component of this product [see Adverse Reactions ( 6.2 ) and Description ( 11.1 )] • Pregnancy or suspicion of pregnancy. Cannot be used for post-coital contraception (emergency contraception) ( 4 ) • Congenital or acquired uterine anomaly if it distorts the uterine cavity ( 4 ) • Acute pelvic inflammatory disease (PID) or a history of PID unless there has been a subsequent intrauterine pregnancy ( 4 ) • Postpartum endometritis or infected abortion in the past 3 months ( 4 ) • Known or suspected uterine or cervical malignancy ( 4 ) • Known or suspected breast cancer or other progestin-sensitive cancer ( 4 ) • Uterine bleeding of unknown etiology ( 4 ) • Untreated acute cervicitis or vaginitis or other lower genital tract infections ( 4 ) • Acute liver disease or liver tumor (benign
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary The use of Skyla is contraindicated in pregnancy or with a suspected pregnancy and Skyla may cause adverse pregnancy outcomes [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 , 5.2 )]. If a woman becomes pregnant with Skyla in place, the likelihood of ectopic pregnancy is increased and there is an increased risk of miscarriage, sepsis, premature labor, and premature delivery . Remove Skyla, if possible, if pregnancy occurs in a woman using Skyla. If Skyla cannot be removed, follow the pregnancy closely [see Warnings and Precautions ( 5.1 , 5.2 )]. There have been isolated cases of virilization of the external genitalia of the female fetus following local exposure to LNG during pregnancy with an LNG IUS in place. Animal reproduction studies have not been conducted with Skyla.
7 interactions on record
Levonorgestrel + FluconazoleModerate
Fluconazole 200 mg increased levonorgestrel AUC by 25%. Fluconazole 50 mg showed no significant difference.
Source: NLP:fluconazole
Levonorgestrel + LamotrigineModerate
Oral contraceptive component decreases lamotrigine concentrations approximately 50% and is itself decreased by 19%.
Source: NLP:lamotrigine
Estrogen-containing oral contraceptives decrease lamotrigine concentrations approximately 50%. Lamotrigine may decrease levonorgestrel component by 19%.
Source: NLP:lamotrigine er
Levonorgestrel + LeflunomideModerate
Teriflunomide may increase systemic exposure of levonorgestrel. Consideration should be given to type or dose of oral contraceptives used with leflunomide.
Source: NLP:leflunomide
Levonorgestrel + PerampanelModerate
FYCOMPA 12 mg daily decreases levonorgestrel exposure by approximately 40%, potentially reducing contraceptive effectiveness. Additional non-hormonal contraception is recommended.
Source: NLP:perampanel
Levonorgestrel + TeriflunomideModerate
Teriflunomide may increase systemic exposure of levonorgestrel. Consideration should be given to the type or dose of contraceptives used.
Source: NLP:teriflunomide